Monitoring of Cerebral Blood Flow in Patients on Extracorporeal Membrane Oxygenation

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a supportive therapy, indicated in case of severe, possibly reversible pulmonary failure, refractory to conventional therapies. Despite advances, morbidity and mortality remain high. Severe neurological complications can occur during ECMO, but their exact etiology is not well understood. It is hypothesized that fast correction of severe hypercapnia, a common indication for venovenous ECMO, may be detrimental for the brain. The supposed mechanism is that fast correction of hypercapnia may result in massive cerebral vasoconstriction and impaired cerebral blood flow (CBF). In this prospective, observational study the aim is to quantify change in CBF during routine initial correction of severe hypercapnia during VV-ECMO. Furthermore, the investigators will record any other hemodynamic changes during VV-ECMO. The hypothesis is that a larger decline in PaCO2 will result in a larger decline of CBF.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• High suspicion of an indication for VV-ECMO;

• Arterial line present to enable blood sampling;

• Older than 18 years.

Locations
Other Locations
Netherlands
Amsterdam UMC
RECRUITING
Amsterdam-zuidoost
Contact Information
Primary
Alexander Vlaar, MD PhD MBA
a.p.vlaar@amsterdamumc.nl
25846
Backup
Rogier Immink, MD PhD
mailto:r.v.immink@amsterdamumc.nl
27182
Time Frame
Start Date: 2021-12-15
Estimated Completion Date: 2025-08-15
Participants
Target number of participants: 15
Treatments
VV-ECMO
Critically ill patients with a suspected indication for VV-ECMO. ECMO will be provided according to local guidelines. In the Amsterdam UMC, location AMC, next to VV-ECMO, veno-arterial (VA-ECMO) is also provided. For this study, only patients on VV-ECMO will be included.
Sponsors
Leads: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

This content was sourced from clinicaltrials.gov